CYP3A酶活性测定方法与依托泊苷个体化给药方案  

Determination method of CYP3A activity and individualization dosage regimen of etoposide

作　　者：张顺国[1] 张健[1] 陈敏玲[1] 

机构地区：[1]上海第二医科大学附属新华医院药剂科,上海200092

出　　处：《中国临床药理学与治疗学》2005年第10期1147-1151,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的：探索白血病患者体内依托泊苷(VP16)浓度与CYP3A酶活性(CA)的相关性。方法：采用HPLC法分别测定20例白血病患者血浆中VP16浓度及尿液CA，进行相关性分析。结果：白血病患者体内VP16浓度与CA无相关性，而与CA的常用对数(1gCA)线性相关，相关系数r=0．969。结论：通过测定CA制定VP16给药方案是可行的。AIM： To explore the correlation between drug concentration of etoposide （VP16） and CYP3A activity （CA） in leukemia. METHODS： The urinary 6β-hydroxycortisol/hydrocortisone ratio is a useful marker for CA. Concentration of VP16 in plasma and CA was determined by HPLC in 20 leucemia patients, and the correlation analysis was performed using the SPSS software. RESULTS： Correlation analysis between drug concentration of VP16 and CA in leukemia was poor correlated （ r = 0.725）, but concentration of VP16 and lgCA showed a good correlated （ r = 0.969）. CONCLUSION： It is feasible to adjust the therapeutic regimen of VP16 by determining CA.

关 键 词：依托泊苷 白血病 CYP3A酶活性 个体化 给药方案 

分 类 号：R969.1[医药卫生—药理学]